CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Paroxetine is a drug of choice in the treatment of major depressive disorder (MDD). Its metabolism has recently been reported to be mediated through the CYP enzymes 1A2 and 2D6. In our current study, we tested whether genetic polymorphisms in CYP1A2 are associated with the treatment efficacy and side effects of paroxetine.
A total of 241 MDD pat...
Alternative Titles
Full title
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_954603507
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_954603507
Other Identifiers
ISSN
1462-2416
E-ISSN
1744-8042
DOI
10.2217/pgs.10.128
